| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Ganoderal A targets the cholesterol biosynthesis pathway. As a cholesterol synthesis inhibitor, it may inhibit key enzymes in the mevalonate pathway, such as HMG-CoA reductase, or interfere with sterol biosynthesis at other steps. This activity makes it relevant for research into hyperlipidemia, atherosclerosis, and other cholesterol-related disorders.
|
|---|---|
| ln Vitro |
In vitro, ganoderal A exhibits cholesterol synthesis inhibitory activity. Its ability to modulate cholesterol metabolism has been characterized in cell-based assays. The compound may also have other biological activities, including antioxidant and anti-inflammatory effects, which are common among triterpenoids from Ganoderma lucidum. Further in vitro studies are needed to fully characterize its pharmacological profile.
|
| ln Vivo |
In vivo, ganoderal A has been studied for its effects on cholesterol metabolism. As a cholesterol synthesis inhibitor, it may reduce serum cholesterol levels in animal models. Its presence in Ganoderma lucidum, a well-known medicinal mushroom, suggests potential health benefits, including cardiovascular protection. However, detailed in vivo pharmacological studies are limited.
|
| Enzyme Assay |
For in vitro enzyme assays, ganoderal A can be evaluated for inhibition of cholesterol synthesis. Cell-free assays using liver microsomes or recombinant enzymes involved in the mevalonate pathway can be performed. The compound is incubated with the enzyme and its substrate, and activity is measured by quantifying the production of mevalonate or other intermediates using radiometric or chromatographic methods. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, ganoderal A is typically tested on hepatocytes or other cell lines involved in lipid metabolism. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-48 hours. Cholesterol synthesis is measured by incorporating radiolabeled acetate or by quantifying cholesterol content using enzymatic assays. Gene expression of cholesterol biosynthesis enzymes can be assessed by qPCR.
|
| Animal Protocol |
For in vivo animal experiments, ganoderal A can be administered orally to rodent models of hyperlipidemia. The compound is typically given at doses ranging from 10-100 mg/kg for 2-4 weeks. Serum lipid profiles (total cholesterol, LDL, HDL, triglycerides) are measured. Liver and adipose tissue cholesterol content can be analyzed. Histopathological examination of liver tissues is performed to evaluate efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ganoderal A are limited. As a triterpenoid with a molecular weight of 436.68 g/mol and formula C₃₀H₄₄O₂, it is expected to have moderate oral bioavailability. The compound is lipophilic and may distribute to lipid-rich tissues. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile. Its solubility in water is very low (3.2 × 10⁻⁵ g/L at 25°C).
|
| Toxicity/Toxicokinetics |
Toxicological data for ganoderal A are limited. As a natural product isolate from Ganoderma lucidum, a mushroom with a long history of safe use in traditional medicine, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human therapeutic use.
|
| References | |
| Additional Infomation |
Ganoderic aldehyde A is a triterpenoid compound. It has been reported that ganoderic aldehyde A exists in Ganoderma lucidum, Ganoderma retusa, and Ganoderma sinense, and relevant data are available for reference.
Ganoderal A is a research-use only compound and has not been approved for clinical applications. It is also known as灵芝醛 A in Chinese. Its molecular weight is 436.68, and its formula is C₃₀H₄₄O₂. The compound is isolated from Ganoderma lucidum, a medicinal fungus used in traditional Chinese medicine. It is available from various research chemical suppliers. |
| Molecular Formula |
C30H44O2
|
|---|---|
| Molecular Weight |
436.6692
|
| Exact Mass |
436.334
|
| CAS # |
104700-98-3
|
| PubChem CID |
13934282
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
551.0±50.0 °C at 760 mmHg
|
| Melting Point |
127-128℃
|
| Flash Point |
202.0±27.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
8.35
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
902
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](CC/C=C(\C)/C=O)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C
|
| InChi Key |
RHNFCIPJKSUUES-SPFFTVLFSA-N
|
| InChi Code |
InChI=1S/C30H44O2/c1-20(19-31)9-8-10-21(2)22-13-17-30(7)24-11-12-25-27(3,4)26(32)15-16-28(25,5)23(24)14-18-29(22,30)6/h9,11,14,19,21-22,25H,8,10,12-13,15-18H2,1-7H3/b20-9+/t21-,22-,25+,28-,29-,30+/m1/s1
|
| Chemical Name |
(E,6R)-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]hept-2-enal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.26 mg/mL (~12.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.53 mg/mL (1.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.53 mg/mL (1.21 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.53 mg/mL (1.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2901 mL | 11.4503 mL | 22.9006 mL | |
| 5 mM | 0.4580 mL | 2.2901 mL | 4.5801 mL | |
| 10 mM | 0.2290 mL | 1.1450 mL | 2.2901 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
